Tag: commercialization

Company News: Curetis AG Signs Up BioLine LLC as Exclusive Distribution Partner for Russia

– Partners to start registration process and market launch in Russia –

Curetis today announced that it has signed up BioLine LLC as an exclusive distribution partner for Russia, Ukraine, Kazakhstan and Belorus. BioLine is a major player in these markets and distributor for global companies such as Becton Dickinson, Leica Microsystems and many others.

BioLine is preparing the registration of the Unyvero™ Solution and the Unyvero™ P50 Pneumonia Application with the Russian Ministry of Health for regulatory clearance to sell the CE-marked IVD in Russia.

There is a huge unmet medical need for better pneumonia diagnostics in the region. According to the WHO, 1.5 million cases of pneumonia occur in Russia each year, of which only about 0.3 to 0.4 million are registered with the authorities. 25-33% of patients experience prolonged duration due to antibiotic resistances. Diagnosis is still poor: it is estimated that 20% of all patients diagnosed with severe flu in Russia are in fact suffering from pneumonia. Mortality from pneumonia is huge, reaching 14-20% in the elderly (≥ 60 years) and up to 25% in young children.

Company News: Curetis AG Chooses Mediphos as Exclusive Distribution Partner for the Netherlands

– Partners prepare market launch and clinical evaluation project –

Holzgerlingen, Germany, September 26, 2012 — Curetis AG today announced that Curetis and Mediphos have closed an exclusive distribution agreement for the Netherlands. Mediphos is an experienced independent distributor with a clear focus on molecular diagnostics and an emphasis on microbiology-based applications.

Under the agreement, both companies will prepare the market roll-out of Curetis´ Unyvero™ Solution and the Unyvero™ P50 Pneumonia Application. Moreover, Mediphos will be responsible for a clinical evaluation project in the Netherlands and will present the Unyvero Solution™ at the autumn meeting of the National Microbiology Association (NVVM) on November 15, 2012.

The Dutch target market for the Unyvero™ Solution covers approximately 40 hospitals (both university and large general hospitals). Significant market research has been jointly conducted by the partners to define a clear-cut execution strategy. Positive feedback from clinical opinion leaders and major hospitals has led to a two-pronged approach: while all target hospitals will be approached in parallel, the first Unyvero™ instrument system will be placed at one of the country’s leading university hospitals where a clinical evaluation by clinical opinion leaders will be initiated right away.

Company News: Curetis AG Signs Distribution Deal in Middle East with ATC

– Kuwait Ministry of Health clears Unyvero™ Solution for clinical evaluation –

Curetis AG, an innovative molecular diagnostics company focusing on the development and commercialization of in-vitro diagnostic products for infectious diseases, today announced that it has signed an exclusive distribution deal for its Unyvero™ solution with Advanced Technology Company K.S.C. (ATC). ATC will become the exclusive distributor of the Unyvero Solution including consumables for the six Gulf Cooperation Council (GCC) countries and the Lebanon.

Placement of instruments will start in the third quarter this year. A clinical evaluation project of the Unyvero™ Solution has been approved by the Kuwait Ministry of Health and will take place at leading clinical sites in the country. Curetis, ATC and the clinical investigators will cooperate closely during this phase, and are planning to publish evaluation data in 2013 at a renowned international medical conference.

Company News: Merus Announces Appointment of Jason Avery as Chief Business Officer

Merus B.V., a biopharmaceutical company focused on multispecific human antibody therapeutics, announced today that Jason Avery has been appointed as Chief Business Officer.

With a professional background as Head of Business Development at Affitech A/S and Chief Business Officer at Cambridge Antibody Technology, Jason Avery brings extensive industry experience to Merus.

“Jason comes to Merus with a wealth of experience in Business Development, in particular in the antibody space, and we are delighted to have him join the team,” said Dr Ton Logtenberg, CEO of Merus B.V. “As our multispecific human antibody platforms have matured and consistently yield lead candidates for clinical development, Jason’s expertise will be invaluable to reach our ambitious business goals.”

“Merus is one of the most impressive companies in the antibody technology and product space,” said Jason Avery. “The combination of MeMo®, the common light-chain transgenic mouse, and Merus’ antibody format technology facilitates unprecedented ease in the discovery, development and manufacturing of bispecific antibodies. I look forward to progressing the commercial success of Merus´ discriminative pipeline of owned and partnered antibody products. I am very excited to be joining such an experienced management team.”

1 2 3